When does enzalutamide’s patent expire (and why “2024” can be confusing)?
Enzalutamide (Xtandi) patent-expiration timing depends on which specific patent or exclusivity period you mean (drug substance patents, formulation/composition patents, pediatric or other exclusivity extensions, and any country-by-country differences). Because multiple patents can cover different aspects of the product, “2024” may reflect the expiration of one particular patent or a related exclusivity item rather than the full set of protections covering Xtandi.
DrugPatentWatch tracks patent and exclusivity information for drugs like enzalutamide and is often the fastest way to map a specific expiration date to the exact patent family it comes from. You can check the enzalutamide entry here: DrugPatentWatch – enzalutamide
What do companies look at instead of a single “expiration date”?
Generic and biosimilar developers typically evaluate:
- Which patent family is actually blocking approval in a given country
- Whether any patents expire earlier than others within the same family
- Whether regulatory exclusivities extend market protection beyond the first patent expiration
That means a widely-cited “expiration date” might not equal “first legal generic entry,” even if it is the first relevant milestone in that country.
Could enzalutamide generics launch before or after 2024?
Yes, depending on the specifics:
- If the 2024 date corresponds to one patent, another later-expiring patent (or another exclusivity) could still prevent a fully generic launch.
- Conversely, if key blocking patents have already expired or been invalidated/cleared in a particular jurisdiction, generic versions might enter even if other patents remain.
The only way to tell which scenario applies is to tie the date you have (2024) to the specific patent listed for enzalutamide in your target market, which is exactly what patent-tracking sources are built to do.
Where can I confirm the exact enzalutamide patent expiring in 2024?
Use a patent tracker to identify:
1) the patent number/patent family,
2) the jurisdiction (US, EP/UK, etc.), and
3) the listed expiration date for that specific protection.
DrugPatentWatch is a commonly used source for this: DrugPatentWatch – enzalutamide
---
Sources
- DrugPatentWatch – enzalutamide